News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxford BioMedica PLC (OXB.L) Interim Results For The Six Months Ended 30 June 2014


8/28/2014 10:25:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Oxford, UK – 28 August 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a world-leading gene and cell therapy company, today announces its unaudited interim results for the six months ended 30 June 2014.

HIGHLIGHTS

OPERATIONAL:

• LentiVector® manufacturing and process development
Novartis development and manufacturing collaboration:
? £3.6 million revenues generated in H1 2014; total revenues now exceed £5 million
AMSCI project gathering momentum:
? Design phase for additional capacity at the manufacturing site nearing completion
• LentiVector® Product Development:
Ocular programmes:
? RetinoStat® patient recruitment and dosing completed; patients now in follow-up phase
? StarGen™ and UshStat® licensed to Sanofi and Phase I/IIa studies fully handed over
? EncorStat® Phase I/II study being planned
CNS programmes:
? ProSavin® Phase I/II study results published in The Lancet
? £2.2 million Technology Strategy Board grant secured for OXB-102 Phase I/II study

FINANCIAL1:

• Revenue of £4.7 million (H1 2013 £2.1 million), including £3.6 million from Novartis collaboration
• Research & Development costs of £6.9 million (H1 2013 £6.8 million)
• Net loss of £4.8 million (H1 2013 £5.9 million)
• Net cash burn2 reduced to £5.0 million (H1 2013 £7.3 million)
• Successful fundraise of £20.1 million net of expenses in June 2014
• Net cash3 at 30 June 2014 of £18.3 million (31 December 2013: £2.2 million)
• Repayment in full of the amount drawn down from the £5 million secured loan facility agreement with the Vulpes Life Sciences Fund

POST PERIOD END HIGHLIGHTS:

• Paul Blake appointed as Chief Development Officer, having served as a non-executive director of the Company since January 2010

1. Unaudited results
2. Net cash used in operating activities plus sales and purchases of non-current assets
3. Cash, cash equivalents and available for sale investments

John Dawson, Chief Executive Officer of Oxford BioMedica, said: “Oxford BioMedica is now a sector-leader within the internationally attractive gene and cell therapy space and our operations are progressing extremely well. Our business model now encapsulates three strands: an unrivalled portfolio of gene therapy products in development; LentiVector® license agreements based on our strong IP and gene delivery system; and revenues from third-party manufacturing & development services. Our platform and strategy is well-validated by our collaborations with Sanofi, Novartis, GSK and Pfizer and our significant recent funding round endorsed this further. Our strategy is to use our model to reach cash-flow break even and we are very well-placed to deliver significant near-term value creation for shareholders.”

An analyst briefing will be held at 09:30am BST on Thursday, 28 August 2014 at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2V 8AE. There will be a simultaneous live conference call and the presentation will be available on the Company’s website at www.oxfordbiomedica.co.uk.

Please visit the website approximately five minutes before the conference call, at 09:25am BST, to download the presentation slides. Conference call details:

Participant dial-in: +44 (0) 1452 555 566
Conference ID: 89288921

An audio replay file will be made available shortly afterwards via the Company's website on the “Media/Download centre/Webcasts and audio” section. Alternatively, you may listen to the replay by dialling the following number:
Dial-in for replay (available until 25-09-2014): +44 (0)1452 550 000
Conference ID: 89288921

For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer

Tel: +44 (0)1865 783 000
Media/Financial Enquiries:
Mary-Jane Elliott/Emma Thompson/Matthew Neal/Laura Thornton
Consilium Strategic Communications
Tel: +44 (0)20 3709 5700

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES